Click Here to Go Directly to the Story
Register/Subscribe
Home


 
 


U.S. EDITION
Full Table of Contents
Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Economic Trends
Industry Insider
Business Outlook

News: Analysis & Commentary
In Business This Week
Washington Outlook
International Business
People
Special Report -- BW/Architectural Record Awards
Developments to Watch
Science & Technology
Finance
Industrial Management

The Corporation
Information Technology
BusinessWeek Lifestyle
BusinessWeek Investor
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials

SMALL BIZ SUPPLEMENT November 5 Table of Contents


INTERNATIONAL EDITIONS
International -- Asian Cover Story
International -- Letter From Paris
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Special Report
International -- Int'l Figures of the Week




NOVEMBER 5, 2001

NEWS: ANALYSIS & COMMENTARY

Cipro: Now for the Downside
With overuse, the anthrax cure will lose its effectiveness

 
  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

Related Items
NEWS: ANALYSIS & COMMENTARY

Productivity: The Real Story

Commentary: How to Get Pharma's Big Guns Aimed at Microbes

Cipro: Now for the Downside

Killer Tests for Deadly Germs

Now, Profits Are in Free Fall

So Much for Detroit's Cash Cushion

Will the EU Go for Microsoft's Jugular?

With the toll from anthrax mounting, the antibiotic most commonly used to tackle the deadly bug is now a celebrity. News anchor Tom Brokaw recently held a bottle up to the camera, saying: "In Cipro we trust."

Sadly, that trust could be short-lived. Cipro "may have the dubious distinction of being the antibiotic we destroy faster than any other," warns microbiologist Abigail A. Salyers at the University of Illinois. The problem is that bacteria are immensely adaptable critters. Expose them to antibiotics long enough, and they'll evolve ways to survive the drugs.

Infectious-disease experts stress that people exposed to anthrax, such as postal workers in affected mail centers, should take Cipro, at least until tests show either that they don't have the bug or that their bacterial strain is susceptible to other drugs. But those who gulp down Cipro merely out of fear are being dangerously irresponsible, putting both themselves and others at risk.

Why? The human body teems with bacteria. A broad-based antibiotic such as Cipro acts like a neutron bomb on this ecosystem, wiping out billions of microbes. Not only can that impair normal body functions in which bacteria play a role, such as digestion, but harmful germs can move in, like squatters taking over suddenly vacant houses.

CRYING WOLF. Worse, antibiotics breed resistance. When you take a drug, the hardiest bacteria among constantly mutating strains survive, reproduce, and pass along defense mechanisms against drugs. Taking Cipro for weeks "is the perfect situation for the regular bacteria in the body to become resistant," says Dr. Carol J. Baker, a pediatrician at Baylor College of Medicine and president of the Infectious Diseases Society of America. Except in the case of an actual anthrax infection--rather than mere exposure--it's best to take the antibiotic for a few days only, to limit the development of resistance in the body's bacteria.

Even without resistance, these normally harmless bugs can turn nasty. Painful infections result when benign gut flora, such as E. coli, find their way to the urinary tract. Streptococcus bugs that live harmlessly in the throat cause pneumonia if they get into the lungs. Contract one of these diseases, and your doctor may prescribe Cipro. But if you've previously taken weeks of the antibiotic, your particular bug may already be primed to resist it. Not until you have to rush to the hospital will anyone know that something has gone horribly wrong. And the resistant microbes can spread to others.

Indeed, antibiotic resistance is one of the world's most pressing public-health problems. A single case of so-called multidrug-resistant tuberculosis costs more than $250,000 to cure--and the deadly germs are on the rise in many countries. Up to 30% of bacteria that cause ear infections and pneumonia in the U.S. can fight off standard antibiotics. The toll: thousands of hospitalizations and billions of dollars a year.

The quinolone drugs--of which Cipro is one example--were once part of the solution. They kill a wide spectrum of bugs, including strains resistant to other drugs. But resistance to quinolones has appeared in everything from meningitis-causing pneumococcus bugs to the E. coli in bladder infections.

It could get worse. Consider China, where quinolones have been widely overused for 10 years. The percentage of resistant E. coli, for one, has shot past 50%, rendering the whole class of drugs almost useless. "Unless we use Cipro wisely," says Dr. Stuart B. Levy of Tufts University, "we may lose one the most important drugs we have."



By John Carey in Washington


Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page

Back to Top

NOVEMBER
TODAY'S MOST POPULAR STORIES

  1. Which Auto Brands Should Go?
  2. Meet Your New Recruits: They Want to Eat Your Lunch
  3. The Brewing Credit-Card Storm
  4. That Wave of Retirees? Not So Big
  5. Facebook's Big Facelift

Get Free RSS Feed >>
  MARKET INFO
DJIA 12986.8 -5.86
S&P 500 1425.35 +1.78
Nasdaq 2528.85 -4.88

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.